Aktis Oncology, Inc. Common stock (AKTS) — Capital Reinvestment Ratio

Latest as of December 2024: 0.19x

Aktis Oncology, Inc. Common stock (AKTS) has a Capital Reinvestment Ratio of 0.19x as of December 2024, meaning it reinvests 0% of its operating cash flow ($14.76 Million) in capital expenditures ($2.86 Million). See AKTS free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.19x
Capex / Operating Cash Flow

Operating Cash Flow

$14.76 Million
USD

Capital Expenditures

$2.86 Million
USD

Data as of

Dec 2024
Most recent filing

Aktis Oncology, Inc. Common stock Capital Reinvestment Ratio (2024–2024)

This chart tracks Aktis Oncology, Inc. Common stock's Capital Reinvestment Ratio across 1 annual periods.

Annual Capital Reinvestment Ratio for Aktis Oncology, Inc. Common stock (2024–2024)

Year-by-year Capital Reinvestment Ratio for Aktis Oncology, Inc. Common stock from 2024 to 2024. For live market cap and broader valuation context, see Aktis Oncology, Inc. Common stock (AKTS) market capitalisation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2024 0.19x $14.76 Million $2.86 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow